» Articles » PMID: 24586581

Risk Factors for Hospital Admission with RSV Bronchiolitis in England: a Population-based Birth Cohort Study

Overview
Journal PLoS One
Date 2014 Mar 4
PMID 24586581
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the timing and duration of RSV bronchiolitis hospital admission among term and preterm infants in England and to identify risk factors for bronchiolitis admission.

Design: A population-based birth cohort with follow-up to age 1 year, using the Hospital Episode Statistics database.

Setting: 71 hospitals across England.

Participants: We identified 296618 individual birth records from 2007/08 and linked to subsequent hospital admission records during the first year of life.

Results: In our cohort there were 7189 hospital admissions with a diagnosis of bronchiolitis, 24.2 admissions per 1000 infants under 1 year (95%CI 23.7-24.8), of which 15% (1050/7189) were born preterm (47.3 bronchiolitis admissions per 1000 preterm infants (95% CI 44.4-50.2)). The peak age group for bronchiolitis admissions was infants aged 1 month and the median was age 120 days (IQR = 61-209 days). The median length of stay was 1 day (IQR = 0-3). The relative risk (RR) of a bronchiolitis admission was higher among infants with known risk factors for severe RSV infection, including those born preterm (RR = 1.9, 95% CI 1.8-2.0) compared with infants born at term. Other conditions also significantly increased risk of bronchiolitis admission, including Down's syndrome (RR = 2.5, 95% CI 1.7-3.7) and cerebral palsy (RR = 2.4, 95% CI 1.5-4.0).

Conclusions: Most (85%) of the infants who are admitted to hospital with bronchiolitis in England are born at term, with no known predisposing risk factors for severe RSV infection, although risk of admission is higher in known risk groups. The early age of bronchiolitis admissions has important implications for the potential impact and timing of future active and passive immunisations. More research is needed to explain why babies born with Down's syndrome and cerebral palsy are also at higher risk of hospital admission with RSV bronchiolitis.

Citing Articles

Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study.

Marouk A, Verrat B, Pontais I, Cojocaru D, Chappuy H, Craiu I Eur J Pediatr. 2025; 184(3):229.

PMID: 40044918 DOI: 10.1007/s00431-025-06050-7.


Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants.

Calomfirescu-Avramescu A, Toma A, Mehedintu C, Nastase L, Dima V Vaccines (Basel). 2025; 13(2).

PMID: 40006718 PMC: 11861343. DOI: 10.3390/vaccines13020171.


A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization.

Cai B, Chen Y, Agosti Y, Schmoele-Thoma B, Koury K, Jansen K Vaccines (Basel). 2025; 12(12.

PMID: 39772012 PMC: 11679883. DOI: 10.3390/vaccines12121351.


A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults.

Mao X, Hua X, Wu C, Ge X, Zhang J, Wu X Clin Transl Sci. 2024; 18(1):e70095.

PMID: 39736101 PMC: 11684469. DOI: 10.1111/cts.70095.


Use of uterine electromyography in the prediction of preterm birth after transvaginal cervical cerclage.

Xie H, Zhu M, Deng K, Yi J, Zhu L, Tan J BMC Pregnancy Childbirth. 2024; 24(1):716.

PMID: 39478448 PMC: 11523863. DOI: 10.1186/s12884-024-06779-3.


References
1.
Saxena S, Bottle A, Gilbert R, Sharland M . Increasing short-stay unplanned hospital admissions among children in England; time trends analysis '97-'06. PLoS One. 2009; 4(10):e7484. PMC: 2758998. DOI: 10.1371/journal.pone.0007484. View

2.
Wang D, Bayliss S, Meads C . Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011; 15(5):iii-iv, 1-124. PMC: 4781126. DOI: 10.3310/hta15050. View

3.
Stensballe L, Hjuler T, Andersen A, Kaltoft M, Ravn H, Aaby P . Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study. Clin Infect Dis. 2008; 46(8):1165-71. DOI: 10.1086/529438. View

4.
Figueras-Aloy J, Carbonell-Estrany X, Quero J . Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004; 23(9):815-20. DOI: 10.1097/01.inf.0000136869.21397.6b. View

5.
Hall C . Respiratory syncytial virus in young children. Lancet. 2010; 375(9725):1500-2. DOI: 10.1016/S0140-6736(10)60401-1. View